Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis
Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-07 · 12 (3)
DOI: 10.1177/20552173261471723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 23.07.2026. Verfasst von Ifat Vigiser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Reliable biomarkers of inflammatory activity in multiple sclerosis (MS) are needed to complement clinical and MRI assessments. Circulating microRNAs (miRNAs) are promising candidates due to their serum stability and involvement in MS-related biological pathways.
Objectives
To evaluate whether selected serum miRNAs can discriminate relapse from remission in treatment-naive patients with relapsing-remitting MS (RRMS).
Methods
In this prospective paired study, newly diagnosed, untreated RRMS patients were sampled during clinical relapse and subsequent remission. A targeted miRNA panel was quantified using quantitative PCR. Differential expressions were assessed using paired statistical testing with multiple comparison correction. Diagnostic performance was evaluated using ROC analysis and multivariate logistic regression. Pathway enrichment analysis was performed using Ingenuity Pathway Analysis.
Results
Twenty patients (40 paired samples) were included. Eight miRNAs were differentially expressed between relapse and remission after Benjamini–Hochberg correction. hsa-miR-122-5p showed the largest fold change (fold change = 3.0; adjusted p = 0.043). A three-miRNA panel (hsa-miR-122-5p, hsa-miR-15b-5p, hsa-miR-30e-5p) demonstrated high discriminative accuracy (area under the curve = 0.88; 95% CI 0.79–0.96). Pathway analysis highlighted inflammatory, metabolic, and hypoxia-related processes.
Conclusions
Circulating miRNAs distinguished relapse from remission in treatment-naive RRMS patients, suggesting their potential as complementary biomarkers of disease activity. These findings should be considered exploratory and require validation in an independent, larger cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Neuroimmunology and Multiple Sclerosis Unit, Neurology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Research Department, Levinsky-Wingate Academic Center, Netanya, Israel.
- Department of Neurology, Assuta Medical Center, Tel Aviv, Israel.
- Department of Neurology, Mayo Clinic in Florida, Jacksonville, FL, USA.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Arnon Karni, Keren Regev
Zitieren
APA
Vigiser, I., Zeevi, Y., Piura, Y., Kolb, H., Golan, M., Karni, A., & Regev, K. (2026). Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(3). https://doi.org/10.1177/20552173261471723
Vancouver
Vigiser I, Zeevi Y, Piura Y, Kolb H, Golan M, Karni A, et al. Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(3). doi:10.1177/20552173261471723
BibTeX
@article{Vigiser2026,
author = {Vigiser, Ifat and Zeevi, Yoav and Piura, Yoav and Kolb, Hadar and Golan, Maya and Karni, Arnon and Regev, Keren},
title = {Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis},
journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
year = {2026},
volume = {12},
number = {3},
doi = {10.1177/20552173261471723}
}
EUVIMED